It is well established that tumours hinder both natural and vaccine‐induced tumour‐specific
CD4+ T‐cell responses. Adoptive T‐cell therapy has the potential to circumvent functional …

We reported previously that vaccination of reconstituted, lymphopenic mice resulted in a
higher frequency of tumor‐specific effector T cells with therapeutic activity than vaccination …

Our understanding of the importance of CD4+ T cells in orchestrating immune responses
has grown dramatically over the past decade. This lymphocyte family consists of diverse …

Abstract CD4+ CD25+ T cells generated in a vaccine scenario can play a critical role in
limiting antitumor therapy, thus having widespread implications for the immunotherapy …

Previously, we have shown that priming of therapeutic CD8+ T cells in tumor vaccine-
draining lymph nodes of mice vaccinated with GM-CSF secreting B16BL6 melanoma cells …

The efficacy of antigen-specific CD8+ CTLs depends not only on the quantity of CTLs
generated but also perhaps, more importantly, on the avidity of the CTLs. To date, however …

We have developed and shown to be efficacious an immunotherapeutic strategy to enhance
the generation of tumor-specific CD4+ T helper lymphocytes. The approach uses autologous …

Difficulties maintaining fully functional CD4+ T cells in culture have historically limited the
study of their role in tumour rejection as well as other clinical applications. As the therapeutic …

Neoantigens resulting from the inherent genomic instability of tumor cells generally do not
trigger immune recognition. Similarly, transfection of tumors with model Ags often fails to …

Immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit. It can
be passive, ie transfer of immune effector cells (T cells) or proteins (antibodies), or active, ie …